Measurement of levels of fractional exhaled nitric oxide in patients with pulmonary tuberculosis
Autor: | Kim Sh, Park Yk, Tae Hyung Kim, Ji-Yong Moon, Shin Dh, Yoon Hj, Ji Young Yhi, Sohn Jw, Min Jh, Park Dw |
---|---|
Rok vydání: | 2016 |
Předmět: |
Pulmonary and Respiratory Medicine
Adult Male medicine.medical_specialty Clinical variables 030231 tropical medicine Antitubercular Agents Nitric Oxide Gastroenterology Body Mass Index 03 medical and health sciences 0302 clinical medicine Pulmonary tuberculosis Internal medicine Medicine Humans In patient 030212 general & internal medicine Tuberculosis Pulmonary integumentary system business.industry Body Weight Case-control study Exhalation respiratory system Middle Aged respiratory tract diseases Infectious Diseases Breath Tests Case-Control Studies Exhaled nitric oxide Female business Body mass index After treatment Biomarkers Follow-Up Studies |
Zdroj: | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 20(9) |
ISSN: | 1815-7920 |
Popis: | Setting The role of fractional exhaled nitric oxide (FeNO) in the diagnosis and treatment of pulmonary tuberculosis (PTB) is uncertain. Objective To examine the value of FeNO as a biomarker for PTB. Design Baseline FeNO levels were compared in 69 PTB patients and 118 healthy controls. The correlation between baseline FeNO levels and clinical variables of tuberculosis were studied. FeNO levels were checked twice in the PTB group, at diagnosis and after 2 months of anti-tuberculosis medication, and factors affecting changes in FeNO levels after treatment were analysed. Results FeNO levels were not significantly different in the PTB group and controls (mean ± standard deviation 27.7 ± 17.6 parts per billion [ppb] vs. 27.0 ± 10.8 ppb, P = 0.531). In a multivariate regression analysis, no variable was shown to affect FeNO levels at diagnosis. FeNO levels did not significantly change after 2 months of treatment (26.8 ± 18.3 ppb vs. 24.0 ± 10.7 ppb, P = 0.257). Only PTB with a high FeNO level (>25 ppb) was related to a decline in FeNO levels after 2 months of treatment. Conclusion FeNO levels do not appear to be affected in PTB patients. |
Databáze: | OpenAIRE |
Externí odkaz: |